Day: March 28, 2024

Announces 2024 GuidanceFigure 1 – Ongoing Installation of the Ball MillOngoing Installation of the Ball MillMONTREAL, March 28, 2024 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA, OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce financial and operational results for the fourth quarter and year ended December 31, 2023. All amounts are in US dollars, unless otherwise stated. Annual HighlightsExceeded 2023 production guidance with silver production of 1.97 million ounces (“oz”), a 5% increase from 2022. Ore processed of 281,634 tonnes (“t”) in 2023, a 10% increase from 254,976t in 2022. 493,340t of ore mined in 2023 for an average of 1,352 tonnes per day (“tpd”), a 79% increase from ore mined in 2022. Revenue of $42.8 million in 2023, a 12% increase from 2022. Beat 2023 cash cost guidance...

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent Developments Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeksMNPR-101-Zr Phase 1 dosimetry clinical trial has Human Research Ethics Committee (HREC) clearance in Australia and is on track to initiate at the Melbourne Theranostic Innovation Centre (MTIC) within the next few weeks.Will enroll patients with advanced cancers, aiming for those most likely to have uPAR expression, which include a majority of all triple-negative breast, colorectal, and...

–-Resubmission of NDA On Track for Early Q2 24— –-Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24– –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2023. “Since we announced positive topline data from our REASSURE trial in January, we’ve made significant progress in completing the new drug application (NDA) for the planned resubmission early in the second quarter,” said Corey Fishman,...

Benefitting from Increased Operating Efficiency and Economies of Scale, Evidenced by 156% Year-Over-Year Increase in Operating Income for the Fourth Quarter of 2023 Reports Net Earnings of $883,000 for the Fourth Quarter of 2023 Conference call to be held today at 10:00 AM ET QUINCY, Mass., March 28, 2024 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the year ended December 31, 2023. Andy Shape, President and CEO of Stran, commented, “We made meaningful progress throughout 2023, resulting in record sales of approximately $75.9 million, a 28.7% increase over the...

Company continues to evaluate strategic options to maximize shareholder value MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates. “As a result of last year’s FDA request for a second Phase 3 trial to support the avasopasem NDA, we have implemented key measures to extend our cash runway and assess strategic alternatives,” said Mel Sorensen, M.D., Galera’s President and CEO. “Among these measures, we recognize that the decision to discontinue our GRECO trials was challenging for our team and our clinical...

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024. Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells (LuminICE-203): Company on track to report initial efficacy and safety data in Q2 2024. AFM28: Currently enrolling patients in the sixth and final cohort of the Phase 1 dose-escalation study in patients with CD123-positive relapsed/refractory (r/r) AML. Restructuring...

(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in FY 2023: C$1.00 = R$3.70) SINGAPORE, March 28, 2024 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: “NPK”) (“Verde” or the “Company”) announces its financial results for the full year ended December 31, 2023 (“FY 2023”) and the fourth quarter 2023 (“Q4 2023”), as audited by Ernst & Young (“EY”). The FY 2023 audited results were consistent with the interim results announced by the Company on January 26, 2024:Metric January 26, 2024 press release FY 2023 Audited resultsSales (tons) 4280,000 428,000Revenue (C$) 37.5 million – 38.5 million 37.9 millionEBITDA (C$) 1.5 million – 2.5 million 2.0 millionNet loss range (C$) 5.0 million – 6.0 million 6.0 millionCDR potential (tons of CO2) 17,680 17,680“Unfortunately,...

Revenue of $60.6 million including $12.6 million from Managed Services Net Income of $6.2 million and Adjusted EBITDA of $62.3 million 9,195 self-mined Bitcoin on balance sheet as of December 31, 2023 MIAMI, March 28, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America’s largest Bitcoin miners, today announced its financial results for the six months ended December 31, 2023. “Our results this period demonstrate the strength and potential of the new Hut 8. Our thesis for the merger was to combine the operating scale and discipline of US Bitcoin Corp with the strong balance sheet, access to capital markets, and liquidity of Hut 8 Mining Corp. Since closing, we have focused tirelessly on driving efficiencies...

Net income was RMB87.7 million for full year 2023Mobile device charging orders1 increased 32.8% year-over-year during the fourth quarter of 2023 SHANGHAI, China, March 28, 2024 (GLOBE NEWSWIRE) — Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter and fiscal year ended December 31, 2023. HIGHLIGHTS FOR THE FOURTH QUARTER AND FULL YEAR 2023Net income was RMB87.7 million for the full year 2023, compared to a net loss of RMB711.2 million for 2022. Mobile device charging orders for the fourth quarter of 2023 was 154.9 million, representing an increase of 32.8% compared to the same period last year. Mobile device charging orders for 2023 was 656.4 million, representing a year-over-year...